Condition
Hematologic Malignancies
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownTrial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...NCT05470491 · 2023-01-26
RECRUITINGDisease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From ChinaNCT06900114 · 2025-02-08
COMPLETEDStudy of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesNCT02743351 · 2016-12-20
COMPLETEDExercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant PatientsNCT03212560 · 2016-10-01
COMPLETEDA Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsNCT02663518 · 2016-01-28
TERMINATEDCommon interventions
Leading sponsors
Trial status mix
COMPLETED3
RECRUITING1
TERMINATED1
Phase mix
PHASE13
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.